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Objective: The aim of this study was to evaluate whether fluconazole (FLZ) could affect the
bioactivity and cellular structure of Candida albicans or Candida glabrata biofilms grown in the
presence of FLZ.
Materials and methods: Tokens were fabricated using poly(methylmethacrylate) resin
(PMMA) in a hot water bath. Salivary pellicles were formed on the PMMA surface, and
biofilms of a reference strain and two clinical isolates of C. albicans (ATCC 90028, P01 and P34)
and C. glabrata (ATCC 2001, P11 and P31) were developed for a period of 48 h. Control and
experimental groups were formed. FLZ at the bioavailable concentration in saliva (2.56 mg/
mL) was added to the medium of the experimental group. The culture mediums of the
control and experimental groups were changed after 24 h. The bioactivities of the biofilms
were evaluated using an XTT reduction colorimetric assay. The cellular structure was
analysed by confocal scanning laser microscopy and by transmission electron microscopy.
The data were analysed by the independent sample Student’s t-test, with the significance
level set at 5%.
Results: The presence of FLZ decreased the bioactivity of all C. albicans biofilms ( p < 0.001),
however, it did not change the cellular structure of C. albicans P34. Regarding the C. glabrata
biofilm bioactivity and structure, no statistically significant differences were found between
the control and experimental groups.
Conclusion: FLZ, at the bioavailable concentration present in saliva, interferes with the
development of C. albicans biofilms, but does not interfere with the development of C.
glabrata biofilms.
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Candida species are commensal microorganisms with a
presence that ranges from 20% to 50% of the microorganisms
in the oral cavity of the healthy dentate population.1 However,* Corresponding author: Tel.: +55 19 2106 5294; fax: +55 19 2106 5211.
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Open access under the Elsevier OA license.under predisposing conditions, Candida spp. can behave as an
opportunistic pathogen causing a variety of infections ranging
from mucosal lesions to severe systemic dissemination.2,3
Amongst these infections, Candida-associated denture stoma-
titis is a common disease that is observed in approximately
45.3% of acrylic denture wearers,4 with Candida albicans being
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Candida glabrata has frequently been isolated from the acrylic
surface and the palatal mucosa, and represents the second
most prevalent fungal pathogen in the oral cavity.4,5
Fluconazole (FLZ) has been the preferred antifungal agent
for the treatment of mucosal and systemic Candida spp.
infections.6 The widespread use of FLZ to treat Candida
infections can be attributed to its high bioavailability, low
hepatotoxicity, reduced cost and the possibility of being
administrated orally or intravenously.6 However, acquisition
of resistance to azole compounds has been recorded with
several organisms, in particular C. albicans.7 Acquired resis-
tance to antifungal agents has been one of the major
problems, as the treatment can lead to selection of micro-
organisms, favouring infections caused by non-albicans Candi-
da species.8,9 In particular infections caused by C. glabrata,
which is naturally more resistant to antifungal treatment, is
strongly associated with generalised systemic infections with
high mortality rates.9,10
Although some studies have been conducted evaluating
the effect of FLZ on Candida biofilms or as planktonic cells,11–14
these studies were conducted using FLZ after biofilm
growth.12,13 However, there have been no previous studies
that have simulated the clinical conditions in which Candida
biofilms were allowed to grow on denture surfaces whilst the
patients were undergoing FLZ therapy, a condition that could
lead to Candida spp. developing resistance to FLZ.
Thus, the aim of the present study was to evaluate whether
FLZ could affect the bioactivity and cellular structure of C.
albicans or C. glabrata biofilms that were grown in the presence
of FLZ.
2. Materials and methods
2.1. Experimental design
This in vitro study had a randomised and blinded design.
Tokens of poly(methylmethacrylate) resin were fabricated
according to the manufacturer’s instructions. After this, the
surface roughness was measured and the tokens were
randomly divided into 12 groups for the biofilm assays.
Biofilms of one reference strain and two clinical isolates of C.
albicans (ATCC 90028, P01 and P34) and C. glabrata (ATCC 2001,
P11 and P31) were allowed to develop on token surfaces.
Control and experimental groups were formed. FLZ at 2.56 mg/
mL, the concentration bioavailable in saliva,15 was added to
the medium of the experimental group. The biofilms were
developed for 48 h, and the bioactivity was evaluated using an
XTT (sodium 30-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-
bis (4-methoxy-6-nitro) benzene sulfonic acid hydrate) reduc-
tion colorimetric assay. Confocal scanning laser microscopy
(CLSM) and transmission electron microscopy (TEM) were
used for cellular structure analyses.
2.2. Preparation of tokens
Tokens were fabricated using acrylic resin polymerised by a
hot water bath (QC-20 PMMA – Dentsply Ltd., Weybridge,
England), according to the manufacturer’s instructions, atroom temperature (25  1 8C) and 50  5% (relative humidity)
under aseptic conditions, using a metal matrix (10 mm
diameter and 2 mm thick). The tokens were immersed in
distilled water at 37 8C for 12 h for residual monomer release.16
Then, the tokens were ground using progressively smoother
aluminium oxide papers (320, 400 and 600 – grit) in a horizontal
polisher (model APL-4; Arotec, Sao Paulo, Brazil). Next, the
tokens were disinfected with 70% alcohol, washed twice with
sterile distilled water and then ultrasonicated for 20 min to
remove any contaminates and residues from the surface.
2.3. Surface roughness measurements
Surface roughness of the acrylic resin tokens was measured
using a profilometer (Surfcorder SE 1700; Kosaka Laboratory
Ltd., Kosaka, Japan) accurate to 0.01 mm with a total
measurement length of 3.2 mm and 0.5 mm/s. Three readings
were made for each token, and a mean value was calculated.17
The average surface roughness obtained was 0.31  0.02 mm.
2.4. Biofilm assay
Biofilm assays were performed using two reference strains: C.
albicans ATCC 90028 and C. glabrata ATCC 2001 and two clinical
isolates of each strain (P01 and P34) and (P11 and P31),
respectively.
The clinical isolates were obtained from the surface of the
acrylic prosthesis of patients without symptoms of oral
candidosis. Before the experimental procedures, the identity
of all isolates was reconfirmed by the CHROMagar1 Candida
test (Difco Laboratories, Detroit, MI, USA) and the carbohy-
drate assimilation test using the Vitek-2 identification system
(bioMe´rieux, Marcy l’Etoile, France).18
Prior to each experiment, each Candida strain was grown
aerobically on Sabouraud dextrose agar at 37 8C for 18 h. Then,
it was inoculated in yeast nitrogen base (YNB) broth (Difco
Laboratories, Detroit, MI, USA) supplemented with 50 mM
glucose and incubated aerobically at 37 8C overnight in an
orbital shaker (model NT 151; Kline Shaker; Nova Tecnica
Laboratory, Sao Paulo, Brazil). When cells were in the
exponential growth phase, they were harvested and washed
twice with 25 mL of phosphate buffered saline (PBS; pH 7.2).
Next, the yeast cells were resuspended in YNB supplemented
with 100 mM glucose and the suspensions were optically
adjusted to a density of 107 cells/mL.
Biofilms were formed on saliva-coated acrylic resin. Equal
volumes of human whole saliva were collected from two
healthy volunteers, who had not used antibiotics, mouth
rinses, or any other medication known to affect salivary
composition and flow in the past 3 months. The volunteers
provided written informed consent previously approved by
the Ethics Committee of Piracicaba Dental School (042/2008).
Stimulated saliva was collected during masticatory stimula-
tion with flexible film (Parafilm M; American Can Co, Neenah,
WI, USA), an ice-chilled polypropylene tube and clarified by
centrifugation at 10,000  g for 5 min at 4 8C. For every
experiment, the saliva sample was collected at the same time
of day and the volume was limited to 50 mL per collection
period, in order to allow for the circadian rhythm in saliva
composition.19 The supernatant was filtered through a
Table 1 – Bioactivity (optical density from XTT assay) of
Candida spp. biofilms (means W s.d.). In the experimental
group was added FLZ at 2.56 mg/mL concentration.
Bioactivity
Control Experimental
C. albicans
ATCC 90028 3.9  0.1 1.0  0.3*
P01 3.5  0.3 0.9  0.3*
P34 3.6  0.2 1.4  0.4*
C. glabrata
ATCC 2001 3.9  0.2 3.9  0.2
P11 3.8  0.2 3.8  0.1
P31 3.9  0.3 3.9  0.1
* Represent statistically significant differences between control
and experimental groups within each Candida strain (t-test;
p < 0.05).
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used.20
Under aseptic conditions, each token was placed inside a
well of a pre-sterilised flat bottomed 24-well tissue culture
plate and 1 mL of saliva was added. The plate was incubated
for 60 min at 37 8C in an orbital shaker.21
Saliva coated tokens were transferred to another pre-
sterilised flat bottomed 24-well tissue culture plate, and 2 mL
of standard yeast cell suspensions (107 cells/mL) were added to
each well and incubated under agitation at 37 8C for 1.5 h
(adhesion phase) in an orbital shaker. After the adhesion
phase, the cell suspensions were aspirated and each token
was gently washed twice with PBS. Afterwards, 2 mL of YNB
medium with 100 mM glucose was added to the control group
and a mixture of YNB with 100 mM glucose and FLZ (Sigma–
Aldrich Corp, St. Louis, MO, USA) at 2.56 mg/mL was added to
the experimental groups.15
The plates were incubated under agitation at 37 8C for 48 h
in an orbital shaker. After the first 24 h of incubation, the
medium was aspirated and the biofilms were washed twice
with PBS, followed by the addition of 2 mL of medium (control
group) or medium with FLZ (experimental group). Then, the
biofilms were returned to an orbital shaker for an additional
24 h prior to analysis.
2.4.1. Bioactivity analysis
Biofilm bioactivity was performed by an XTT reduction assay
as previously described.22 The XTT solution was prepared by
dissolving the XTT salt (Sigma–Aldrich Corp, St. Louis, MO,
USA) in PBS containing 200 mM glucose. The final concentra-
tion of XTT was 1 mg/mL.22 The solution was filter-sterilised
and stored frozen at 70 8C until use. Menadione (Sigma–
Aldrich Corp, St. Louis, MO, USA) solution (0.4 mM in acetone)
was prepared immediately before each assay. For each assay,
the XTT solution was thawed on ice and mixed with the
menadione solution at 20:1 (v/v).
Tokens with biofilm were gently placed inside another pre-
sterilised flat bottomed 24-well tissue culture plate and 2 mL of
the XTT solution (PBS + 200 mM glucose-XTT-menadione)
were added to each well. The plates were covered with
aluminium foil and incubated in the dark under agitation at
37 8C for 3 h.22 Thereafter, the solution was centrifuged and
500 mL were transferred to spectrophotometer cuvettes. The
bioactivity assay was performed using a spectrophotometer
(Beckman Coulter, Indianapolis, IN, USA) and the readings
were recorded at 490 nm. The bioactivity assays were
performed in triplicate in three independent experiments
on different days (n = 9).
2.4.2. Structure analysis
The tokens with biofilms were gently placed inside pre-
sterilised flat bottomed 24-well tissue culture plates and
stained using a Live/Dead BacLight viability kit (Invitrogen-
Molecular Probes, Eugene, OR, USA). A kit consisting of SYTO-9
and propidium iodide (PI) was used. STYO-9 is a green
fluorescent nucleic acid stain, generally labelling both live
and dead microorganisms. PI, in contrast, is a red-fluorescent
nucleic acid stain and penetrates only the cells with damaged
membranes, thus only the dead cells are visualised. Biofilms
were incubated with SYTO-9 and PI at 30 8C for 20 min in thedark before CLSM analyses. The images of stained biofilms
were captured using a CLSM system (Leica Microsystems CMS,
Mannheim, Germany).
A series of images were obtained for each position at 1 mm
intervals in the z-axis to obtain a three dimensional view of the
biofilms (from substratum to the top of the biofilms). Five
representative randomly selected positions from each corner
and the middle of the tokens were examined for each token, in
two independent experiments on different days (n = 10). The
same protocol and configurations were used for CLSM analysis
(63 objective lens without zoom) in order to obtain all images
from control or experimental groups.
COMSTAT analysis is a software program for quantification
of three-dimensional biofilm structures. It analyses stacks of
images acquired with CLSM. Z-series images of biofilms after
48 h were collected by CLSM. The z-slices of the images were
exported to COMSTAT software and analysed. The parameters
analysed included bio-volume, average thickness and black
spaces of the biofilm. The bio-volume (mm3/mm2) is defined as
the number of stained cell pixels in all images [(pixel
size)x  (pixel size)y  (pixel size)z] divided by the substratum
area of the image stack.23
2.4.3. Cellular structure analysis
The tokens were placed inside a polypropylene tube contain-
ing 3 mL of sterilised PBS. Adherent micro-organisms were
removed from the tokens by sonication at 7 W for 30 s.24 Once
disaggregated, the cells were centrifuged (3000 rpm). The
pellets were fixed by immersion in Karnovsky solution
prepared in 0.1 M cacodylate buffer (pH 7.2) for 6 h at 4 8C
and post-fixed with 1% osmium tetroxide in 0.1 M cacodylate
buffer (pH 7.2) for 1 h at room temperature. After this, the
samples were dehydrated in increasing concentrations of
acetone (50%, 70%, 80% and 90%) and three immersions in pure
acetone (5 min each). Next, Dr. Spurr resin was allowed to
infiltrate into the pellet. For this, three different ratios of
acetone/resin and times of incubation at room temperature
were used: 3:1 (4 h), 1:1 (overnight) and 1:2 (8 h). Then, pure
resin was added to the pellet for a further 24 h followed by one
more addition of resin to the pellet. This set was placed in an
oven for 48 h at 60 8C. After this period, the material was cut
Table 2 – Bio-volume (mm3/mm2), average thickness (mm), average of black spaces (mm) of Candida spp. biofilms
(means W s.d.). In the experimental group was added FLZ at 2.56 mg/mL concentration.
Bio-volume Average thickness Black spaces
Control Experimental Control Experimental Control Experimental
C. albicans
ATCC 90028 13.9  1.7 22.5  1.5* 12.9  1.7 21.5  1.5* 7.4  0.9 11.7  0.7*
P01 16.4  3.7 19.9  3.3* 15.4  3.7 18.90  3.8* 8.7  1.8 10.4  1.6*
P34 19.3  4.9 18.3  4.6 18.3  4.9 17.3  4.6 10.1  2.5 9.6  2.3
C. glabrata
ATCC 2001 14.2  4.6 15.7  3.5 13.2  4.6 14.7  3.5 7.6  2.3 8.3  1.7
P11 16.8  6.0 15.4  2.5 15.8  6.0 14.4  2.5 8.9  3.0 8.2  1.2
P31 13.3  3.6 14.8  2.4 12.3  3.6 13.8  2.4 7.1  1.8 7.9  1.2
* Represent statistically significant differences between control and experimental groups within each Candida strain (t-test; p < 0.05).
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glass blades to obtain semi-fine cuts 1 mm thick. These cuts
were stained with 1% toluidine blue in sodium borate. Next,
the samples were trimmed and 70–90 nm thick cuts were
obtained using an ultramicrotome MT2C (Sorvall Porter Blum,
Newtown, CT, USA), equipped with a diamond blade. The cuts
were collected on copper grids and contrasted with uranyl
acetate and lead citrate. The grids containing the cuts were
analysed by an EM-900 transmission electron microscope (Carl
Zeiss, Oberkochen, Germany), operating at an acceleration
voltage of 50 kV.
2.5. Statistical analysis
The variables used for statistical analysis were bioactivity and
structure (cell bio-volume, thickness and black spaces). TheFig. 1 – CLSM 3D reconstruction of the biofilm z-slices of C. albican
albicans P01 (C – control group, D – experimental group) and C. alb
experimental group was added FLZ at 2.56 mg/mL concentrationnormality of errors distribution and the degree of non-
constant variance were checked for each response variable
using the SAS/LAB package (SAS Software, version 9.0, SAS
Institute Inc., Cary, NC, USA) and data were transformed as
suggested by the software, according to Box et al.25 As the
mean values of bioactivity were not normally distributed,
these data were transformed by exponentiation (y2.3). The
comparison between control and experimental group, for each
strain, was performed using the independent sample Stu-
dent’s t-test. The significant limit was set at 5%.
3. Results
The bioactivity and structure of C. glabrata biofilms were not
altered by the presence of FLZ ( p > 0.05) (Tables 1 and 2, Fig. 3).s ATCC 90028 (A – control group, B – experimental group), C.
icans P34 (E – control group, F – experimental group). In the
.
Fig. 2 – CLSM z-slices of biofilm images of C. albicans ATCC 90028 (A – control group, B – experimental group), C. albicans P01
(C – control group, D – experimental group) and C. albicans P34 (E – control group, F – experimental group). Live cells appear
green, dead cells appear red and black spaces are shown in black (BS). It is possible to observe a considerable increase in cell
volume in images B and D. In the experimental group was added FLZ at 2.56 mg/mL concentration. (For interpretation of the
references to colour in this figure legend, the reader is referred to the web version of the article.)
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found for C. albicans biofilms ( p < 0.001) developed in the
presence of FLZ. The bioactivity decreased 75% for ATCC 90028
and P01, and 60% for P34 (Table 1).
The structure of C. albicans ATCC 90028 ( p < 0.001) and P01
biofilms ( p < 0.05) was affected by FLZ, as shown by the
increase in their thickness, cell bio-volume and black spaces
(Table 2, Fig. 1). C. albicans P34 strains showed no alteration in
the structure of the biofilms developed in the presence of FLZ
(Table 2).
In the z-slices of C. albicans biofilms, increases in the cell
volume and the amount of black space between cells of C.
albicans ATCC 90028 and P01, were observed in the presence of
FLZ (Fig. 2). However, these findings were not seen in the C.
albicans P34 experimental group (Fig. 2).
FLZ caused alterations in the structure of some cells of C.
albicans ATCC 90028 and P01. These changes included an
increase in the amount of vacuoles and nuclei with deformed
shapes (Fig. 4). As in the CLSM images, the TEM images showed
an increase in the cell volume of C. albicans ATCC 90028 andP01 developed in the presence of FLZ (Fig. 4). The cells in Fig. 4
are representative of cells present in the samples.
4. Discussion
Although the effect of FLZ on Candida biofilms has been
extensively investigated in literature,11,13,14,26,27 there is little
information regarding biofilms developed in the constant
presence of FLZ.12,13 The present biofilm growth model
simulated in vivo conditions in which patients wearing
dentures are under a FLZ therapy regimen. Despite FLZ
treatment, in some cases biofilms continued to develop over
the dentures. Thus, understanding the behaviour of Candida
spp. biofilm growth under FLZ therapy may be important for
the development of protective approaches to Candida-related
diseases.
The bioactivity of C. glabrata was not altered by the
presence of FLZ. These findings are in contrast with those
by Konopka et al.13 who used FLZ at the same or higher
Fig. 3 – CLSM 3D reconstruction of the biofilm z-slices of C. glabrata ATCC 2001 (A – control, B – experimental group), C.
glabrata P11 (C – control group, D – experimental group) and C. glabrata P31 (E – control group, F – experimental group). In the
experimental group was added FLZ at 2.56 mg/mL concentration.
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glabrata biofilms were more sensitive to FLZ than C. albicans
biofilms. Nevertheless, the present study corroborates other
reports, which have demonstrated that C. glabrata is naturally
more resistant to treatment with FLZ than C. albicans.9,26,28 The
resistance to FLZ acquired by Candida, especially C. glabrata,
has been reported to involve efflux pumps. These pumps are
constituted by proteins in the cell membrane that pump the
drug out of the cells, reducing the intracellular drugFig. 4 – TEM images showing the ultrastructure of C.
albicans ATCC 90028: (A) control group, (B) experimental
group (with FLZ at 2.56 mg/mL). The nucleus (N) and
vacuoles (V) are shown. The cells developed in the
presence of FLZ (B) presented a deformed nucleus and a
significant increase in the number of vacuoles.concentration to a level at which FLZ has no effect on the
cell.9,29
The present study showed that the C. albicans biofilms
developed in the presence of FLZ, at a bioavailable concentra-
tion in saliva (2.56 mg/mL), reduced the metabolic activity by
60% for P34 and 75% for ATCC 90028 and P01. The results of this
study differ from the findings of Kanopka et al.13 who did not
find a significant reduction in the metabolic activity of C.
albicans biofilms developed for 48 h and then treated with FLZ
at concentrations 3.0 mg/mL for another 24 h. A previous
study, conducted by Chandra et al.,12 showed that when using
concentrations less than 64 mg/mL, the C. albicans biofilms did
not reach a 50% reduction in metabolic activity. The fact that
the biofilms were grown in the constant presence of FLZ may
have influenced the lower bioactivity in the experimental
group of the present study, whilst Chandra et al.12 and
Kanopka et al.13 grew the biofilms first, and afterwards
incubated these biofilms with FLZ. Moreover, the differences
found between the studies may be related to the different
strains and to the fact that in the present study the
experimental group was exposed to a new dose of the drug
every 24 h, considering that the half-life of FLZ ranges from 27
to 37 h.28
The bioactivity of the C. albicans biofilms in the presence of
FLZ was reduced as shown in other studies, but it is important
to highlight that the novel aspect of the present study is that
biofilms were grown in the constant presence of FLZ. The
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that a previous study showed that there was not a linear
relationship between the number of cells and bioactivity.
Moreover, this ratio is not always constant amongst the
Candida species, including C. albicans.30 For this reason, the
present study used CLSM as an auxiliary method of analysis to
assist the XTT assay, considering that CLSM allows biofilms to
be evaluated with their three dimensional structures pre-
served. Additionally, COMSTAT software was used, which
numerically evaluates the biofilm structure.23,31
Regarding biofilm structure, FLZ did not alter the thickness,
bio-volume and black spaces of C. glabrata and C. albicans P34
biofilms. As mentioned, C. glabrata is naturally more resistant
to FLZ treatment.9,26,28 Nevertheless, the fact that the
structure of C. albicans P34 was not changed, although the
metabolic activity was reduced by 60%, could be related to the
ability of Candida to reduce its metabolic activity as a
protective mechanism in adverse situations,9,29 which in the
present study was the presence of FLZ.
Although, C. albicans ATCC 90028 and P01 showed reduced
metabolic activity in the presence of FLZ, an increase in bio-
volume and the average thickness were found. These findings
may be related to the increase in cell volume and in the
amounts of black spaces, which may be occupied by the
polysaccharide matrix and diffusion channels as showed by
CLSM images. Also, the TEM images showed that cells grown
in the presence FLZ seemed bigger with an altered structure
with deformed nucleus and a significant increase in the
number of vacuoles. These vacuoles could be correlated to the
action of FLZ, which inhibits ergosterol biosynthesis, a
component of the fungal membranes. With this inhibition,
toxic substances that are ergosterol precursors accumulate in
the cell, probably in these vacuoles.26,29
The results showed that the structure of C. albicans ATCC
90028 and P01 were altered by FLZ, but this drug was not able to
prevent the development of these biofilms. Further studies are
necessary to determine whether these structural alterations
are related to a response due to FLZ exposure that causes
increased virulence of these biofilms.
5. Conclusion
Within the limits of this study it can be concluded that C.
albicans biofilms developed under the presence of FLZ, at the
bioavailable concentration present in saliva had its bioactivity
and structure altered, but the same was not observed for C.
glabrata biofilms.
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